Pharmaceutical

InMed Pharmaceuticals shared an update to investors on the advancements of their proprietary technology for the microbial biosynthesis of cannabinoids.

InMed Pharmaceuticals (CSE:IN; OTCQB:IMLFF) shared an update to investors on the advancements of their proprietary technology for the microbial biosynthesis of cannabinoids.
As quoted in the press release:

InMed has successfully demonstrated that it can selectively produce all four “gateway” cannabinoids using genetically engineered microorganisms. These molecules can be functionalized further to produce any of the 90+ “downstream” cannabinoids found naturally in the cannabis plant. The company is actively employing this production chassis to synthesize compounds for its pharmaceutical research programs.
Eric A. Adams, President & CEO states, “Successful scale-up and commercialization of the biosynthesis process for cannabinoid production is a top priority for InMed.

Click here to read the full press release.

Source: www.newswire.ca

MARKETS

Markets
TSX18480.98-521.70
TSXV578.06-24.88
DOW29590.41-486.27
S&P 5003693.23-64.76
NASD10867.93-198.88
ASX6574.70-125.50

COMMODITIES

Commodities
Gold1643.40+0.50
Silver18.870.00
Copper3.35-0.12
Palladium2070.95+11.79
Platinum859.50+4.63
Oil79.43-4.06
Heating Oil3.16-0.16
Natural Gas6.84-0.25

DOWNLOAD FREE REPORTS

×